Literature DB >> 22074744

Outcome after implantable cardioverter-defibrillator in patients with Brugada syndrome: the Gulf Brugada syndrome registry.

Amin Daoulah1, Alawi A Alsheikh-Ali, Ali H Ocheltree, Sara Ocheltree, Salem Al-Kaabi, Majed Malik, Abdul-Karim Al-Habib, Adel Hamed, Najib Al-Rawahi, Ali Al-Sayegh, Saad Al-Hasaniah, Eijaz Ul-Haq.   

Abstract

BACKGROUND AND
OBJECTIVE: Among patients with Brugada syndrome (BS) and aborted cardiac arrest, syncope, or inducible ventricular fibrillation at electrophysiologic study (EPS), the only currently recommended therapy is an implantable cardioverter-defibrillator (ICD), but these are not without complications. We assessed the total number of shocks (appropriate and inappropriate) and complications related to ICD in patients with BS. METHODS AND
RESULTS: Twenty-five patients implanted with ICD for BS in 6 Gulf centers between January 1, 2002, and December 31, 2010, were reviewed. Implantable cardioverter-defibrillator indication was based on aborted cardiac arrest (24%), syncope (56%), or in asymptomatic patients with positive EPS (20%). During a follow-up of 41.2 ± 17.6 months, 3 patients (all with prior cardiac arrest) had appropriate device therapy. Four patients developed complications; 3 of them had inappropriate shocks.
CONCLUSION: In our cohort, appropriate device therapy was limited to cardiac arrest survivors, whereas none of those with syncope and/or positive EPS had arrhythmias. Overall complication rate was relatively high, including inappropriate ICD shocks.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22074744     DOI: 10.1016/j.jelectrocard.2011.10.002

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  5 in total

1.  The Gulf Implantable Cardioverter-defibrillator Registry: Rationale, Methodology, and Implementation.

Authors:  Alawi A Alsheikh-Ali; Ahmad S Hersi; Adel K S Hamad; Ahmed R Al Fagih; Faisal M Al-Samadi; Abdulmohsen M Almusaad; Fayez A Bokhari; Fawzia Al-Kandari; Bandar S Al-Ghamdi; Najib Al Rawahi; Nidal Asaad; Salem Alkaabi; Amin Daoulah; Hosam A Zaky; Omer Elhag; Yahya S Al Hebaishi; Raed Sweidan; Haitham Alanazi; David Chase; Hani Sabbour; Mohammad Al Meheiri; Ismail Al Abri; Mohammad Amin; Khaled Dagriri; Adil O Ahmed; Azam Shafquat; Shahul Hameed Khan
Journal:  Heart Views       Date:  2015 Oct-Dec

Review 2.  Risk factors for cardiac events in patients with Brugada syndrome: A PRISMA-compliant meta-analysis and systematic review.

Authors:  Wenqing Wu; Li Tian; Jinshan Ke; Yi Sun; Ruixia Wu; Jianfang Zhu; Qinmei Ke
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

3.  Spontaneous type 1 pattern, ventricular arrhythmias and sudden cardiac death in Brugada Syndrome: an updated systematic review and meta-analysis.

Authors:  Ahmed Bayoumy; Meng-Qi Gong; Ka Hou Christien Li; Sunny Hei Wong; William Kk Wu; Guang-Ping Li; George Bazoukis; Konstantinos P Letsas; Wing Tak Wong; Yun-Long Xia; Tong Liu; Gary Tse
Journal:  J Geriatr Cardiol       Date:  2017-10       Impact factor: 3.327

Review 4.  Brugada syndrome in children - Stepping into unchartered territory.

Authors:  Shashank P Behere; Steven N Weindling
Journal:  Ann Pediatr Cardiol       Date:  2017 Sep-Dec

Review 5.  Implantable cardioverter-defibrillator in Brugada syndrome: Long-term follow-up.

Authors:  Ibrahim El-Battrawy; Gretje Roterberg; Volker Liebe; Uzair Ansari; Siegfried Lang; Xiaobo Zhou; Martin Borggrefe; Ibrahim Akin
Journal:  Clin Cardiol       Date:  2019-08-22       Impact factor: 2.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.